Changes in antipsychotics and other psychotropic drugs during a 30-month lifestyle intervention among outpatients with schizophrenia

References

• Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch Gen Psychiatry. 2007;64:1123–1131.
   PubMed Web of Science ®Google Scholar
• Brown S, Kim M, Mitchell C, et al. Twenty-five year mortality of a community cohort with schizophrenia. Br J Psychiatry. 2010;196:116–121.
   PubMed Web of Science ®Google Scholar
• Nordentoft M, Wahlbeck K, Hallgren J, et al. Excess mortality, causes of death and life expectancy in 270,770 patients with recent onset of mental disorders in Denmark, Finland and Sweden. PLoS One. 2013;8:e55176.
   PubMed Web of Science ®Google Scholar
• Laursen TM, Nordentoft M, Mortensen PB. Excess early mortality in schizophrenia. Annu Rev Clin Psychol. 2014;10:425–448.
   PubMed Web of Science ®Google Scholar
• Olfson M, Gerhard T, Huang C, et al. Premature mortality among adults with schizophrenia in the United States. JAMA Psychiatry. 2015;72:1172–1181.
   PubMed Web of Science ®Google Scholar
• Ballon JS, Pajvani U, Freyberg Z, et al. Molecular pathophysiology of metabolic effects of antipsychotic medications. Trends Endocrinol Metab. 2014;25:593–600.
   PubMed Web of Science ®Google Scholar
• Gonçalves P, Araújo JR, Martel F. Antipsychotics-induced metabolic alterations: focus on adipose tissue and molecular mechanisms. Eur Neuropsychopharmacol. 2015;25:1–16.
   PubMed Web of Science ®Google Scholar
• Laursen TM, Munk-Olsen T, Gasse C. Chronic somatic comorbidity and excess mortality due to natural causes in persons with schizophrenia or bipolar affective disorder. PLoS One. 2011;6:e24597.
   PubMed Web of Science ®Google Scholar
• Danish Health and Medicines Authority. Medicinsk behandling af voksne diagnosticeret med skizofreni [Medical treatment of adults diagnosed with schizophrenia]. Copenhagen: Danish Health and Medicines Authority; 2014. Danish.
   Google Scholar
• Correll CU, Robinson DG, Schooler NR, et al. Cardiometabolic risk in patients with first-episode schizophrenia spectrum disorders: baseline results from the RAISE-ETP study. JAMA Psychiatry. 2014;71:1350–1363.
   PubMed Web of Science ®Google Scholar
• Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382:951–962.
   PubMed Web of Science ®Google Scholar
• Buchanan RW, Kreyenbuhl J, Kelly DL, et al. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull. 2010;36:71–93.
   PubMed Web of Science ®Google Scholar
• Barnes TR, Paton C. Antipsychotic polypharmacy in schizophrenia: benefits and risks. CNS Drugs. 2011;25:383–399.
   PubMed Web of Science ®Google Scholar
• Hasan A, Falkai P, Wobrock T, et al. World federation of societies of biological psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. World J Biol Psychiatry. 2013;14:2–44.
   PubMed Web of Science ®Google Scholar
• Pendlebury J, Bushe CJ, Wildgust HJ, et al. Long-term maintenance of weight loss in patients with severe mental illness through a behavioural treatment programme in the UK. Acta Psychiatr Scand. 2007;115:286–294.
   PubMed Web of Science ®Google Scholar
• Weiser P, Becker T, Losert C, et al. European network for promoting the physical health of residents in psychiatric and social care facilities (HELPS): background, aims and methods. BMC Public Health. 2009;9:315.
   PubMed Web of Science ®Google Scholar
• Hjorth P, Davidsen AS, Kilian R, et al. Improving the physical health of long-term psychiatric inpatients. Aust N Z J Psychiatry. 2014;48:861–870.
   PubMed Web of Science ®Google Scholar
• Munk-Jørgensen P. Protokol: Indsats mod tidlig død af somatiske årsager blandt mennesker med psykisk sygdom. [Protocol: Action against premature death of somatic causes among people with mental illness]. Aarhus: Region Midtjylland; 2012. Danish.
   Google Scholar
• Munk-Jorgensen P, Blanner Kristiansen C, Uwawke R, et al. The gap between available knowledge and its use in clinical psychiatry. Acta Psychiatr Scand. 2015;132:441–450.
   PubMed Web of Science ®Google Scholar
• Dixon LB, Dickerson F, Bellack AS, et al. The 2009 schizophrenia PORT psychosocial treatment recommendations and summary statements. Schizophr Bull. 2010;36:48–70.
   PubMed Web of Science ®Google Scholar
• Firth J, Cotter J, Elliott R, et al. A systematic review and meta-analysis of exercise interventions in schizophrenia patients. Psychol Med. 2015;45:1343–1361.
   PubMed Web of Science ®Google Scholar
• The ICD-10 Classification of Mental and Behavioural Disorders - Diagnostic criteria for research. Geneva: World Health Organization; 1992.
   Google Scholar
• Nordentoft M, Melau M, Iversen T, et al. From research to practice: how OPUS treatment was accepted and implemented throughout Denmark. Early Interv Psychiatry. 2015;9:156–162.
   PubMed Web of Science ®Google Scholar
• ATC/DDD Index 2016. Norway:WHO Collaborating Centre for Drug Statistics Methodology: 2015 [cited 2016 October 4]. Available from: http://www.whocc.no/atc_ddd_index/
   Google Scholar
• Danish Health and Medicines Authority. Vejledning om behandling med antipsykotiske lægemidler til personer over 18 år med psykotiske lidelser [Guideline for treatment with antipsychotic drugs in adults with psychotic disorders]. Copenhagen: Danish Health and Medicines Authority; 2014. Danish.
   Google Scholar
• RADS. Background paper on medical treatment of psychotic disorders, version 1.4. The Danish Council for the use of expensive hospital medicines; 2013.
   Google Scholar
• Hasan A, Falkai P, Wobrock T, et al. World federation of societies of biological psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry. 2012;13:318–378.
   PubMed Web of Science ®Google Scholar
• Chan J, Sweeting M. Combination therapy with non-clozapine atypical antipsychotic medication: a review of current evidence. J Psychopharmacol. 2007;21:657–664.
   PubMed Web of Science ®Google Scholar
• Stahl SM. Antipsychotic polypharmacy: evidence based or eminence based? Acta Psychiatr Scand. 2002;106:321–322.
   PubMed Web of Science ®Google Scholar
• Baandrup L, Gasse C, Jensen VD, et al. Antipsychotic polypharmacy and risk of death from natural causes in patients with schizophrenia: a population-based nested case-control study. J Clin Psychiatry. 2010;71:103–108.
   PubMed Web of Science ®Google Scholar
• Singh SP, Singh V, Kar N, et al. Efficacy of antidepressants in treating the negative symptoms of chronic schizophrenia: meta-analysis. Br J Psychiatry. 2010;197:174–179.
   PubMed Web of Science ®Google Scholar
• Rummel C, Kissling W, Leucht S. Antidepressants for the negative symptoms of schizophrenia. Cochrane Database Syst Rev. 2006:CD005581.
   PubMed Web of Science ®Google Scholar
• Baandrup L, Østrup Rasmussen J, Klokker L, et al. Treatment of adult patients with schizophrenia and complex mental health needs – a national clinical guideline. Nord J Psychiatry. 2016;70:231–240.
   PubMed Web of Science ®Google Scholar
• Billioti de Gage S, Begaud B, Bazin F, et al. Benzodiazepine use and risk of dementia: prospective population based study. BMJ. 2012;345:e6231.
   PubMed Web of Science ®Google Scholar
• Holt RI, Pendlebury J, Wildgust HJ, et al. Intentional weight loss in overweight and obese patients with severe mental illness: 8-year experience of a behavioral treatment program. J Clin Psychiatry. 2010;71:800–805.
   PubMed Web of Science ®Google Scholar
• Juel A, Kristiansen CB, Madsen NJ, et al. Interventions to improve lifestyle and quality-of-life in patients with concurrent mental illness and substance use. Nord J Psychiatry. 2017;71:197–204.
   PubMed Web of Science ®Google Scholar
• Hjorth P, Medici CR, Juel A, et al. Improving quality of life and physical health in patients with schizophrenia: a 30-month program carried out in a real-life setting. Int J Soc Psychiatry. 2017;63:287–296.
   PubMed Web of Science ®Google Scholar
• Hansen MV, Hjorth P, Kristiansen CB, et al. Reducing cardiovascular risk factors in non-selected outpatients with schizophrenia. Int J Soc Psychiatry. 2016;62:369–376.
   PubMed Web of Science ®Google Scholar
• Carbon M, Correll CU. Clinical predictors of therapeutic response to antipsychotics in schizophrenia. Dialogues Clin Neurosci. 2014;16:505–524.
   PubMed Web of Science ®Google Scholar
• Crespo-Facorro B, Pelayo-Teran JM, Perez-Iglesias R, et al. Predictors of acute treatment response in patients with a first episode of non-affective psychosis: sociodemographics, premorbid and clinical variables. J Psychiatr Res. 2007;41:659–666.
   PubMed Web of Science ®Google Scholar